← Leaderboards
Stephen J Meltzer
University Of Maryland Baltimore
$26,520,343
Attributed
$31,204,573
Total exposure
19
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$31,204,573 · 19
By mechanism
R01$20,213,485 · 12
U01$6,599,070 · 2
UH3$2,812,869 · 1
UG3$861,132 · 1
R21$574,076 · 2
T32$143,941 · 1
Top collaborators
- Tza-Huei Jeff Wang9 shared
- Florin Selaru4 shared
- De-Chen Lin2 shared
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsLesionSamplingBaseMethylationEarly DiagnosisCarcinogenesisMolecularSpecimenStagingDna MethylationCohortCellsEndoscopyTumor ProgressionInsightDiagnosisBiomarkerBiological MarkersDysplasiaGenesEventFutureGene Expression
Grant awards (76)
Academic-Industrial Partnership for Barrett's Esophagus Detection and Risk Assessment$752,603
R01 · FY2025 · CA · contact PI
Modeling Pathways of Early Growth Dysregulation at the GEJ$706,758
R01 · FY2025 · DK · contact PI
Point-of-Care Diagnosis of Esophageal Cancer in LMICs$544,343
U01 · FY2025 · CA · contact PI
Point-of-Care Diagnosis of Esophageal Cancer in LMICs$62,251
U01 · FY2025 · CA · contact PI
Academic-Industrial Partnership for Barrett's Esophagus Detection and Risk Assessment$791,370
R01 · FY2024 · CA · contact PI
Modeling Pathways of Early Growth Dysregulation at the GEJ$731,451
R01 · FY2024 · DK · contact PI
Point-of-Care Diagnosis of Esophageal Cancer in LMICs$576,573
U01 · FY2024 · CA · contact PI
Point-of-Care Diagnosis of Esophageal Cancer in LMICs$620,532
U01 · FY2023 · CA · contact PI
Academic-Industrial Partnership for Non-invasive Barrett's Esophagus Detection$747,752
R01 · FY2022 · DK · contact PI
Facile screening for esophageal cancer in LMICs$936,336
UH3 · FY2021 · CA · contact PI
Academic-Industrial Partnership for Non-invasive Barrett's Esophagus Detection$747,752
R01 · FY2021 · DK · contact PI
Facile screening for esophageal cancer in LMICs$936,336
UH3 · FY2020 · CA · contact PI
Academic-Industrial Partnership for Non-invasive Barrett's Esophagus Detection$747,752
R01 · FY2020 · DK · contact PI
Facile screening for esophageal cancer in LMICs$940,197
UH3 · FY2019 · CA · contact PI
Academic-Industrial Partnership for Non-invasive Barrett's Esophagus Detection$747,752
R01 · FY2019 · DK · contact PI
Academic-Industrial Partnership for Non-invasive Barrett's Esophagus Detection$763,689
R01 · FY2018 · DK · contact PI
Facile screening for esophageal cancer in LMICs$430,847
UG3 · FY2018 · CA · contact PI
(PQC-1) Driver Events In IBD-Associated Neoplastic Progression$613,138
R01 · FY2017 · CA · contact PI
Facile screening for esophageal cancer in LMICs$430,285
UG3 · FY2017 · CA · contact PI
(PQC-1) Driver Events In IBD-Associated Neoplastic Progression$613,138
R01 · FY2016 · CA · contact PI
(PQC-1) Driver Events In IBD-Associated Neoplastic Progression$613,138
R01 · FY2015 · CA · contact PI
(PQC-1) Driver Events In IBD-Associated Neoplastic Progression$613,138
R01 · FY2014 · CA · contact PI
The temporal epigenomic program of Barrett's neoplastic progression$348,999
R01 · FY2013 · DK · contact PI
Inflammatory Bowel Disease-Associated Malignant Transformation$273,649
R01 · FY2013 · CA · contact PI
The temporal epigenomic program of Barrett's neoplastic progression$361,656
R01 · FY2012 · DK · contact PI
The Role of microRNA Alterations in Barrett's Carcinogenesis$330,091
R01 · FY2012 · CA · contact PI
Inflammatory Bowel Disease-Associated Malignant Transformation$291,116
R01 · FY2012 · CA · contact PI
The temporal epigenomic program of Barrett's neoplastic progression$348,849
R01 · FY2011 · DK · contact PI
The Role of microRNA Alterations in Barrett's Carcinogenesis$330,091
R01 · FY2011 · CA · contact PI
Inflammatory Bowel Disease-Associated Malignant Transformation$291,116
R01 · FY2011 · CA · contact PI
The temporal epigenomic program of Barrett's neoplastic progression$361,597
R01 · FY2010 · DK · contact PI
The Role of microRNA Alterations in Barrett's Carcinogenesis$340,300
R01 · FY2010 · CA · contact PI
Inflammatory Bowel Disease-Associated Malignant Transformation$300,120
R01 · FY2010 · CA · contact PI
The temporal epigenomic program of Barrett's neoplastic progression$381,807
R01 · FY2009 · DK · contact PI
Comprehensive Biomarker Development in early Esophagogas$368,444
U01 · FY2009 · CA · contact PI
The Role of microRNA Alterations in Barrett's Carcinogenesis$340,300
R01 · FY2009 · CA · contact PI
Inflammatory Bowel Disease-Associated Malignant Transformation$300,120
R01 · FY2009 · CA · contact PI
Comprehensive Biomarker Development in early Esophagogas$502,584
U01 · FY2008 · CA · contact PI
Comprehensive Biomarker Development in early Esophagogas$164,000
U01 · FY2008 · CA · contact PI
Comprehensive Biomarker Development in early Esophagogas$489,484
U01 · FY2007 · CA · contact PI
The Human Colorectal Instabilitome$365,431
R01 · FY2007 · CA · contact PI
Neoplastic Complications in Inflammatory Bowel Disease$311,092
R01 · FY2007 · CA · contact PI
Comprehensive Biomarker Development in early Esophagogas$489,683
U01 · FY2006 · CA · contact PI
Genomics: Esophageal Metaplasia-Associated Malignancy$399,348
R01 · FY2006 · CA · contact PI
The Human Colorectal Instabilitome$375,197
R01 · FY2006 · CA · contact PI
Neoplastic Complications in Inflammatory Bowel Disease$188,487
R01 · FY2006 · CA · contact PI
Neoplastic Complications in Inflammatory Bowel Disease$74,250
R01 · FY2006 · CA · contact PI
Comprehensive Biomarker Development in early Esophagogas$443,630
U01 · FY2005 · CA
Genomics: Esophageal Metaplasia-Associated Malignancy$371,250
R01 · FY2005 · CA
The Human Colorectal Instabilitome$348,975
R01 · FY2005 · CA
Neoplastic Complications in Inflammatory Bowel Disease$262,795
R01 · FY2005 · CA
Novel Methylation Targets in Gastric Cancer$148,500
R21 · FY2005 · CA
Research Training in Gastroenterology$143,941
T32 · FY2005 · DK
Validation studies of circulating methylation biomarkers$93,407
R21 · FY2005 · CA
Validation studies of circulating methylation biomarkers$35,169
R21 · FY2005 · CA
Comprehensive Biomarker Development in early Esophagogas$434,305
U01 · FY2004 · CA
Genomics: Esophageal Metaplasia-Associated Malignancy$371,250
R01 · FY2004 · CA
The Human Colorectal Instabilitome$348,975
R01 · FY2004 · CA
Neoplastic Complications in Inflammatory Bowel Disease$256,716
R01 · FY2004 · CA
Novel Methylation Targets in Gastric Cancer$148,500
R21 · FY2004 · CA
COMPREHENSIVE BIOMAKER DEVELOPMENT IN EARLY ESOPHAGOGAST$476,216
U01 · FY2003 · CA
Genomics: Esophageal Metaplasia-Associated Malignancy$371,250
R01 · FY2003 · CA
The Human Colorectal Instabilitome$348,975
R01 · FY2003 · CA
Neoplastic Complications in Inflammatory Bowel Disease$262,937
R01 · FY2003 · CA
Novel Methylation Targets in Gastric Cancer$148,500
R21 · FY2003 · CA
COMPREHENSIVE BIOMAKER DEVELOPMENT IN EARLY ESOPHAGOGAST$462,344
U01 · FY2002 · CA
Genomics: Esophageal Metaplasia-Associated Malignancy$371,250
R01 · FY2002 · CA
HUMAN COLORECTAL INSTABILITOME$139,863
R01 · FY2002 · CA
COMPREHENSIVE BIOMAKER DEVELOPMENT IN EARLY ESOPHAGOGAST$448,877
U01 · FY2001 · CA
HUMAN COLORECTAL INSTABILITOME$341,203
R01 · FY2001 · CA
NEOPLASTIC COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE$117,318
R01 · FY2001 · DK
COMPREHENSIVE BIOMAKER DEVELOPMENT IN EARLY ESOPHAGOGAST$435,804
U01 · FY2000 · CA
HUMAN COLORECTAL INSTABILITOME$331,263
R01 · FY2000 · CA
IGFIR IN HUMAN GI TUMORS$247,290
R01 · FY2000 · CA
NEOPLASTIC COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE$219,128
R01 · FY2000 · DK
COMPREHENSIVE BIOMAKER DEVELOPMENT IN EARLY ESOPHAGOGAST$80,000
U01 · FY2000 · CA